Gene Marcial
Gene Marcial (RSS)
InvestorPlace Contributor

Read complete bio
Recent Articles

Xerox: Making Progress on the Comeback Path

Apr. 27, 2012, 10:50 am EST – Its transition to a digital world is steadily taking shape. Wall Street isn't paying much attention, but XRX could be a long-term turnaround bet. More 

Cue the Biotech M&A Attack!

Apr. 20, 2012, 9:58 am EST – A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road. More 

ConocoPhillips’ Happy Divorce

Apr. 16, 2012, 10:34 am EST – The spin-off of the refining operations is good news for investors. More 

Here Comes a Bidding War for Amylin

Apr. 2, 2012, 7:15 am EST – Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share. More 

What the Bears Miss About Las Vegas Sands

Mar. 23, 2012, 10:29 am EST – Investors under-appreciate the growth opportunities in Macau and Singapore. More 

Pony Up for American Express

Mar. 16, 2012, 9:05 am EST – Stress test winner American Express has it all: Solid financial footing, growing revenues and profits, a newly raised dividend -- and an alluring valuation. More 

This Small-Cap Telecom Deserves Your Attention

Mar. 9, 2012, 8:55 am EST – Cincinnati Bell is mulling a spin-off that would unlock a lot of value. It's attracting some big-money interest -- and you should be watching it, too. More 

Why Starbucks Is Still Steaming Hot

Mar. 2, 2012, 12:29 pm EST – Innovative products, improved customer service and new efforts in Europe and India should keep the java giant growing for years to come. More 

Mattel Is Serious Fun for Investors

Feb. 24, 2012, 8:48 am EST – The No. 1 toymaker's stock keeps rolling -- and its dividend keeps rising -- as it continues to keep the hit toys coming in markets around the world. More 

Why Illumina’s Future Remains Bright

Feb. 17, 2012, 9:15 am EST – Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects. More